Cutaneous Fribrosis Treatment Market
Global Market Study on Cutaneous Fibrosis Treatment: Increasing Prevalence of Scleroderma & Keloids to fuel the demand for Cutaneous Fibrosis Treatment Drugs
The Cutaneous Fibrosis Treatment Market is Highly Fragmented with a Number of Global as Well as Regional Players
The cutaneous fibrosis treatment market is highly fragmented with number of regional as well as global players in the cutaneous fibrosis treatment market, and it is mainly dominated by large pharma companies with vast as well as diverse product portfolios. Whereas, regional players in the cutaneous fibrosis treatment market also hold significant share which makes the cutaneous fibrosis treatment market highly fragmented.
Manufacturers in the market are focusing on developing novel cutaneous fibrosis treatment formulations, since there is no cure available currently. Players in the market are competing on the basis of their regional product footprint, product offerings, and prices of the drugs of same class. The cutaneous fibrosis treatment market is dominated by Pfizer Inc., Novartis AG, Merck & Co. Inc. and other key players.
Manufacturers are largely engaging in developing drugs for cutaneous fibrosis treatment and rare diseases such as scleroderma which also comes under cutaneous fibrosis. The advantages of being designed as the orphan drug for treatment of rare diseases often helps manufacturers to cope with high expenditure on clinical trials and due to this reason small and medium companies are also opting for drug development by investing in research and development.
Find Out More about the Report Coverage
- Pfizer Inc.
- F. Hoffman - La Roche Ltd. (Genentech, Inc.)
- Boehringer Ingelheim International GmbH
- Jubilant Cadista
- Horizon Pharma USA, Inc.
- Bristol-Myers Squibb Company
Increasing Diagnosis Further Improving the Treatment Seeking Rate
Cutaneous fibrosis generally affects people suffering with diseases such as keloids, GvHD, scleroderma, radiation therapies. Cutaneous fibrosis is a rare disease. Limited awareness among healthcare professionals as well as the general population delays the diagnosis and treatment of cutaneous fibrosis.
In the last decade, vast studies around the cutaneous fibrosis treatment are being carried out to evaluate treatment options, epidemiology of the disease which are ultimately helping to understand the prognosis of the disease.
The prevalence of the cutaneous fibrosis is yet to be decided precisely but the prevalence of the associated conditions such as scleroderma and keloids is well established in majority part of the world. Various studies (surveys) by healthcare groups either sponsored by manufacturers or healthcare organizations expected to focus more evaluating cutaneous fibrosis treatment as well as evaluation of epidemiology which is expected to drive the growth of cutaneous fibrosis treatment market.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Increasing Prevalence of Cutaneous Fibrosis Associated Conditions
The increasing prevalence of cutaneous fibrosis-associated conditions, such as scleroderma, keloids (severe form), Graft Versus Host Disease (GVHD), and other conditions, is expected to drive the growth of cutaneous fibrosis treatment market. Scleroderma and other cutaneous fibrosis - associated diseases are more prevalent in persons aged above 35 to 40 years.
The aging population of the world, especially in the developed regions, is expected to boost the prevalence of cutaneous fibrosis-associated indications, which is, in turn, increasing the prevalence of cutaneous fibrosis. In 2016, around 12.4% of the population of Asia Pacific was aged 60 years and above, which is expected to increase to 25% by 2050. The aging population is growing at faster rate in developing countries as compared to developed countries.
For instance, France took over 115 years to transform from an aging to aged society, whereas China is expected to take only 25 years for a similar transition. The prevalence of keloid scars related to physical injuries is also expected to increase with an increase in the number of surgeries, road accidents, and trauma injuries. Fibrosis is associated with various diseases as a morbidity and is a cause of mortality in more than 40% of the deaths occurring in the US.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Increasing Number of Clinical Trials
There is no approved therapy for the cutaneous fibrosis treatment. Not a single drug has been approved for the cutaneous fibrosis treatment, which has led drug manufacturers to evaluate the efficacy and action of various drugs for the cutaneous fibrosis treatment. Various companies are evaluating different molecules for the cutaneous fibrosis treatment.
For example, miRagen Therapeutics, Inc. is evaluating the REMLARSEN (MRG-201) for the cutaneous fibrosis treatment, and it is currently in the Phase 2 of clinical trials. Various other companies are also focusing on diseases with high unmet needs. The largely unmet needs in the cutaneous fibrosis treatment further underlines the untapped treatment-wise as well as revenue generation-wise potential
Explore Persistence Market Research’s expertise in promulgation of the business !
Cutaneous Fibrosis Treatment Market: Competitive Landscape
This part of the report consists of the profiles of the key players in the Cutaneous Fibrosis treatment market based on their market shares, product offerings, differential strategies, marketing approach, and company dashboard.
A few of the important players featured in the Cutaneous Fibrosis treatment market report include Novartis AG, Pfizer Inc., Genentech, Inc. (Merck & Co. Inc.), Sanofi S.A., Boehringer Ingelheim International GmbH, Jubilant Cadista, Horizon Pharma USA, Inc., and Bristol-Myers Squibb Company.
Cutaneous Fibrosis: Definition
Cutaneous fibrosis is the accumulation of extracellular matrix (ECM) components in the dermis, leading to compromised function and altered architecture of the dermis. Development of fibrosis occurs naturally during scar formation in wound repair or is a pathological process in pro-fibrotic diseases.
Cutaneous Fibrosis Treatment Market: About the Report
The company conducted a research study on the cutaneous fibrosis treatment market for the forecast period 2018 to 2026. The report offers a comprehensive evaluation of the business opportunities prevailing in the cutaneous fibrosis treatment market, with insights on the prices, current trends, prevalence of cutaneous fibrosis, and reimbursement scenario in the cutaneous fibrosis treatment market.
Cutaneous Fibrosis Treatment Market: Segmentation
The report offers a comprehensive taxonomy of the market based on the drug class, route of administration, indication, distribution channel, and region. By drug class, the cutaneous fibrosis treatment market is segmented into corticosteroids, anti-fibrotic drugs, immunotherapy and immunoglobulins.
By route of administration, the cutaneous fibrosis treatment market is segmented as oral, injectable and topical. By indication, the cutaneous fibrosis treatment market is segmented into keloid, scleroderma, radiation-induced cutaneous fibrosis and GvHD associated cutaneous fibrosis.
By distribution channel, the cutaneous fibrosis treatment market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and drug stores. The cutaneous fibrosis treatment market has been analysed across the regions of North America, Latin America, Europe, Asia Pacific Excluding Japan, Japan, Oceania, and the Middle East & Africa (MEA).
Additional Questions Answered
Some of the additional questions addressed in this report on the cutaneous fibrosis treatment market:
- What is the overall revenue generation potential of the cutaneous fibrosis treatment market across the regions?
- Who are the key regional and global competitors? What are their portfolios in the cutaneous fibrosis treatment market?
- Epidemiology of the cutaneous fibrosis.
- What are the major challenges influencing the growth of the cutaneous fibrosis treatment market?
The market has been estimated based on a supply-demand approach. The market was first calculated based on the epidemiology of cutaneous fibrosis in different regions/countries. Some of the other qualitative factors analysed include awareness level and the availability of drugs for cutaneous fibrosis treatment for different indications.
This information is further validated with rigorous primary research (which includes interviews, surveys, in-person interactions, and the viewpoints of seasoned analysts) and secondary research (which includes verified paid sources, authentic trade journals, and resourceful databases).
The research study on the cutaneous fibrosis treatment market also includes the top trends and the macro- as well as micro-economic factors shaping the cutaneous fibrosis treatment market. With this approach, the report on the cutaneous fibrosis treatment market estimates the industry attractiveness of every major segment in the market over the forecast period.